Ostrolenk Faber LLP
Intellectual Property Attorneys
Ostrolenk Faber LLPFirmPracticeAttorneysResourcesPublicationsContact Us

Ostrolenk Faber is a premier intellectual property boutique law firm. Since 1929, we have specialized in domestic and international patent, trademark and copyright law matters. We handle all aspects of IP law from counseling clients to prosecuting their applications to litigating their disputes. Our client base spans from Fortune 500 companies to privately owned businesses to individual inventors. They operate in fields as diverse as consumer electronics, luxury goods, entertainment, pharmaceuticals, and industrial products. With over 75 years of history, we have participated in the development of intellectual property law and gained the experience necessary to best serve our clients now and in the future. Read More


Ostrolenk Partner To Participate In AIPLA 2014 Mid-Winter Institute

OSTROLENK partner Robert C. Faber is speaking at the AIPLA 2014 Mid-Winter Institute. Mr. Faber, who is the current author of the treatise Faber on Mechanics of Patent Claim Drafting, will speak on the topic of inequitable conduct as it pertains to patent practitioners. The program will take place in Phoenix, AZ on January 29th - February 1, 2014. For more information regarding the program and for registration information click here.


Resale of Copyrighted Works From Foreign Sellers Is Permissible

On March 19, 2013, the U.S. Supreme Court, in Kirtsaeng v. John Wiley & Sons, ruled that the "first sale doctrine" in copyright law allows the reselling of copyrighted works lawfully manufactured abroad and imported into the United States.  To read the full decision click here.  To Read More Click Here.

 


As Seen In… Forbes

Fluent in the Languages of Technology and Law


 

 

Isolated Human Genes Do Not Constitute Patentable Subject Matter

On June 13, 2013 the U.S. Supreme Court in, Association For Molecular Pathology, et al. v. Myriad Genetics, Inc., et al., unanimously ruled that isolated human genes cannot be patented, but that synthetically produced genetic material may be patented.

Myriad Genetics, Inc. (Myriad) had obtained several patents after discovering the precise location and sequence of the BRCA1 and BRCA2 genes, mutations of which can dramatically increase the risk of breast and ovarian cancer.  Scientists who challenged the patents argued that their ability to carry out research and testing involving these genes was being hindered by the patents at issue.  While not a factor in the case, the particular genes had received significant public attention.   Actress Angelina Jolie revealed in May that she had undergone a preventative double mastectomy after learning that she had inherited a faulty copy of a gene that placed her at high risk for developing breast cancer.  Read More.






Follow us on Facebook


 
1180 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10036 / TELEPHONE: 212.382.0700 / FACSIMILE: 212.382.0888